{"id":68799,"date":"2013-09-12T10:19:27","date_gmt":"2013-09-12T09:19:27","guid":{"rendered":"http:\/\/blog.cofb.cat\/?p=2949"},"modified":"2013-09-12T10:19:27","modified_gmt":"2013-09-12T09:19:27","slug":"futur-de-la-formulacio-magistral-comunicacio-amb-el-metge-i-tractaments-personalitzats","status":"publish","type":"post","link":"https:\/\/www.cofb.org\/es\/2013\/09\/12\/futur-de-la-formulacio-magistral-comunicacio-amb-el-metge-i-tractaments-personalitzats\/","title":{"rendered":"Futuro de la formulaci\u00f3n magistral: comunicaci\u00f3n con el m\u00e9dico y tratamientos personalizados"},"content":{"rendered":"<p>\u201cHay muchos pacientes que necesitan la adecuaci\u00f3n de los tratamientos y la formulaci\u00f3n magistral es una respuesta: \u00e9sta es una de las razones por las que tiene una excelente perspectiva en los pr\u00f3ximos a\u00f1os\u201d. Son palabras de <b>Francesc Llamb\u00ed<\/b>, presidente de Aprofarm y vocal del Colegio de Farmac\u00e9uticos de Barcelona, quien ha <b>apuntado las claves para que la formulaci\u00f3n magistral sea una herramienta de futuro<\/b>. Lo ha hecho en el marco del Congreso 2013 de la FIP (International Pharmaceutical Federation), celebrado en Dubl\u00edn del 31 de agosto al 5 de septiembre.<\/p>\n<p><a href=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2013\/09\/francesc-llambi.jpg\"><img decoding=\"async\" class=\"wp-image-2953  alignright\" title=\"Francesc Llamb\u00ed\" alt=\"francesc-llambi\" src=\"http:\/\/blog.cofb.cat\/wp-content\/uploads\/2013\/09\/francesc-llambi-200x300.jpg\" width=\"108\" height=\"162\" \/><\/a><\/p>\n<p>[tabs type=\u201dhorizontal\u201d][tab_title][\/tab_title][tab]Una de las conclusiones aportadas por Llamb\u00ed es que \u201cLa formulaci\u00f3n magistral encontrar\u00e1 su sitio en el futuro si sabemos c\u00f3mo encontrar aplicaciones minoritarias para principios activos ya registrados , establecer una buena comunicaci\u00f3n con los m\u00e9dicos para una mejor prescripci\u00f3n de tratamientos personalizados y detectar \u00e1reas con un volumen importante de poblaci\u00f3n que necesite la adecuaci\u00f3n de los tratamientos a necesidades especiales no cubiertas por las presentaciones comercializadas\u201d[\/tab][\/tabs]<\/p>\n<p>Durante su ponencia, incluida en la sesi\u00f3n de formulaci\u00f3n magistral del Congreso \u2013<i>El rol de compounding in closing therapeutic gaps<\/i>-, Llamb\u00ed aport\u00f3 casos y referencias cient\u00edficas recientes que avalan el importante papel de la formulaci\u00f3n magistral en los \u00faltimos quince a\u00f1os, con la incorporaci\u00f3n de un importante n\u00famero de principios activos (tacrolimus -inmunodepresor-, tazaroteno -antiacn\u00e9ico, antipsori\u00e1sico-, prednicarbato -glucocorticoide-, calcipotriol -antipsori\u00e1sico-, etc.), veh\u00edculos (dermocosm\u00e9ticos, aceites, lacas, espumas, lollipops, etc.) y sus extraordinarios resultados como herramienta para la personalizaci\u00f3n de los tratamientos.<\/p>\n<p>Los argumentos aportados por el experto demostraron que la formulaci\u00f3n magistral cumple todas y cada una de las <b>siete utilidades<\/b> encomendadas a la formulaci\u00f3n magistral actualmente:<\/p>\n<p><strong><span style=\"color: #888888;\">1.<\/span><\/strong> cubrir huecos terap\u00e9uticos;<\/p>\n<p><strong><span style=\"color: #888888;\">2.<\/span><\/strong> dar respuesta terap\u00e9utica en el caso de medicaciones que han dejado de comercializarse pero que siguen siendo la primera opci\u00f3n de tratamiento, por ejemplo en casos como la dermatitis herpetiforme y la queratosis act\u00ednica;<\/p>\n<p><strong><span style=\"color: #888888;\">3.<\/span><\/strong> facilitar la administraci\u00f3n del medicamento, ya sea en el tratamiento de patolog\u00edas que coexisten (ros\u00e1cea y dermatitis seborreica, acn\u00e9 y melasma) o bien en la optimizaci\u00f3n de las cantidades especialmente en el tratamiento de \u00e1reas extensas;<\/p>\n<p><strong><span style=\"color: #888888;\">4.<\/span> <\/strong>ayudar en los casos de alergias e intolerancias;<\/p>\n<p><strong><span style=\"color: #888888;\">5.<\/span><\/strong> la individualizaci\u00f3n de los tratamientos, tanto a trav\u00e9s del ajuste de las dosis como del cambio de veh\u00edculo o la combinaci\u00f3n de distintos principios activos cuando es conveniente;<\/p>\n<p><strong><span style=\"color: #888888;\">6.<\/span><\/strong> la reducci\u00f3n de reacciones adversas;<\/p>\n<p><strong><span style=\"color: #888888;\">7.<\/span> <\/strong>cumplir con otros requerimientos en pacientes hospitalizados.<\/p>\n<p>&nbsp;<\/p>\n<p>El presidente de Aprofarm y vocal del Colegio de Farmac\u00e9uticos de Barcelona comparti\u00f3 sesi\u00f3n con expertos de todo el mundo, que pusieron el \u00e9nfasis en diferentes aspectos de la formulaci\u00f3n magistral, desde normativas o est\u00e1ndares de calidad, hasta las sus aplicaciones en otras \u00e1reas como la pedi\u00e1trica o las precauciones de farmac\u00e9uticos de todo el mundo a la hora de formular.<\/p>","protected":false},"excerpt":{"rendered":"<p>\u201cHay muchos pacientes que necesitan la adecuaci\u00f3n de los tratamientos y la formulaci\u00f3n magistral es una respuesta: \u00e9sta es una de las razones por las que tiene una excelente perspectiva en los pr\u00f3ximos a\u00f1os\u201d. Son palabras de Francesc Llamb\u00ed, presidente de Aprofarm y vocal del Colegio de Farmac\u00e9uticos de Barcelona, quien [...]<\/p>","protected":false},"author":1,"featured_media":2993,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_uag_custom_page_level_css":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[32],"tags":[650],"class_list":["post-68799","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-noticies-farmacia","tag-formulacio-magistral"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Futur de la formulaci\u00f3 magistral: comunicaci\u00f3 amb el metge i tractaments personalitzats - Col\u00b7legi de Farmac\u00e8utics de Barcelona<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/novaorg.cofb.net\/2013\/09\/12\/futur-de-la-formulacio-magistral-comunicacio-amb-el-metge-i-tractaments-personalitzats\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Futur de la formulaci\u00f3 magistral: comunicaci\u00f3 amb el metge i tractaments personalitzats - Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"og:description\" content=\"\u201cHi ha molts pacients que necessiten l\u2019adequaci\u00f3 dels tractaments i la formulaci\u00f3 magistral n\u2019\u00e9s una resposta: aquesta \u00e9s una de les raons per les quals t\u00e9 una excel\u00b7lent perspectiva en els propers anys\u201d. S\u00f3n paraules de Francesc Llamb\u00ed, president d\u2019Aprofarm i vocal del Col\u00b7legi de Farmac\u00e8utics de Barcelona, qui ha [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/novaorg.cofb.net\/2013\/09\/12\/futur-de-la-formulacio-magistral-comunicacio-amb-el-metge-i-tractaments-personalitzats\/\" \/>\n<meta property=\"og:site_name\" content=\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\" \/>\n<meta property=\"article:published_time\" content=\"2013-09-12T09:19:27+00:00\" \/>\n<meta name=\"author\" content=\"wpAdminCofbOrg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:site\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"wpAdminCofbOrg\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/novaorg.cofb.net\/2013\/09\/12\/futur-de-la-formulacio-magistral-comunicacio-amb-el-metge-i-tractaments-personalitzats\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2013\/09\/12\/futur-de-la-formulacio-magistral-comunicacio-amb-el-metge-i-tractaments-personalitzats\/\"},\"author\":{\"name\":\"wpAdminCofbOrg\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb\"},\"headline\":\"Futur de la formulaci\u00f3 magistral: comunicaci\u00f3 amb el metge i tractaments personalitzats\",\"datePublished\":\"2013-09-12T09:19:27+00:00\",\"dateModified\":\"2013-09-12T09:19:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2013\/09\/12\/futur-de-la-formulacio-magistral-comunicacio-amb-el-metge-i-tractaments-personalitzats\/\"},\"wordCount\":510,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2013\/09\/12\/futur-de-la-formulacio-magistral-comunicacio-amb-el-metge-i-tractaments-personalitzats\/#primaryimage\"},\"thumbnailUrl\":\"\",\"keywords\":[\"Formulaci\u00f3 magistral\"],\"articleSection\":[\"Not\u00edcies farm\u00e0cia\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/novaorg.cofb.net\/2013\/09\/12\/futur-de-la-formulacio-magistral-comunicacio-amb-el-metge-i-tractaments-personalitzats\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/novaorg.cofb.net\/2013\/09\/12\/futur-de-la-formulacio-magistral-comunicacio-amb-el-metge-i-tractaments-personalitzats\/\",\"url\":\"https:\/\/novaorg.cofb.net\/2013\/09\/12\/futur-de-la-formulacio-magistral-comunicacio-amb-el-metge-i-tractaments-personalitzats\/\",\"name\":\"Futur de la formulaci\u00f3 magistral: comunicaci\u00f3 amb el metge i tractaments personalitzats - Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"isPartOf\":{\"@id\":\"https:\/\/www.cofb.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2013\/09\/12\/futur-de-la-formulacio-magistral-comunicacio-amb-el-metge-i-tractaments-personalitzats\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2013\/09\/12\/futur-de-la-formulacio-magistral-comunicacio-amb-el-metge-i-tractaments-personalitzats\/#primaryimage\"},\"thumbnailUrl\":\"\",\"datePublished\":\"2013-09-12T09:19:27+00:00\",\"dateModified\":\"2013-09-12T09:19:27+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2013\/09\/12\/futur-de-la-formulacio-magistral-comunicacio-amb-el-metge-i-tractaments-personalitzats\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/novaorg.cofb.net\/2013\/09\/12\/futur-de-la-formulacio-magistral-comunicacio-amb-el-metge-i-tractaments-personalitzats\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/novaorg.cofb.net\/2013\/09\/12\/futur-de-la-formulacio-magistral-comunicacio-amb-el-metge-i-tractaments-personalitzats\/#primaryimage\",\"url\":\"\",\"contentUrl\":\"\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/novaorg.cofb.net\/2013\/09\/12\/futur-de-la-formulacio-magistral-comunicacio-amb-el-metge-i-tractaments-personalitzats\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inici\",\"item\":\"https:\/\/novaorg.cofb.net\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Futur de la formulaci\u00f3 magistral: comunicaci\u00f3 amb el metge i tractaments personalitzats\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cofb.org\/#website\",\"url\":\"https:\/\/www.cofb.org\/\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cofb.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.cofb.org\/#organization\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"url\":\"https:\/\/www.cofb.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"contentUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"width\":500,\"height\":105,\"caption\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\"},\"image\":{\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\",\"https:\/\/twitter.com\/farmaceuticsbcn\",\"https:\/\/www.instagram.com\/farmaceuticsbcn\/\",\"https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb\",\"name\":\"wpAdminCofbOrg\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g\",\"caption\":\"wpAdminCofbOrg\"},\"sameAs\":[\"http:\/\/192.168.64.122\/wordpress\"],\"url\":\"https:\/\/www.cofb.org\/es\/author\/wpadmincofborg\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Futur de la formulaci\u00f3 magistral: comunicaci\u00f3 amb el metge i tractaments personalitzats - Col\u00b7legi de Farmac\u00e8utics de Barcelona","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/novaorg.cofb.net\/2013\/09\/12\/futur-de-la-formulacio-magistral-comunicacio-amb-el-metge-i-tractaments-personalitzats\/","og_locale":"es_ES","og_type":"article","og_title":"Futur de la formulaci\u00f3 magistral: comunicaci\u00f3 amb el metge i tractaments personalitzats - Col\u00b7legi de Farmac\u00e8utics de Barcelona","og_description":"\u201cHi ha molts pacients que necessiten l\u2019adequaci\u00f3 dels tractaments i la formulaci\u00f3 magistral n\u2019\u00e9s una resposta: aquesta \u00e9s una de les raons per les quals t\u00e9 una excel\u00b7lent perspectiva en els propers anys\u201d. S\u00f3n paraules de Francesc Llamb\u00ed, president d\u2019Aprofarm i vocal del Col\u00b7legi de Farmac\u00e8utics de Barcelona, qui ha [&hellip;]","og_url":"https:\/\/novaorg.cofb.net\/2013\/09\/12\/futur-de-la-formulacio-magistral-comunicacio-amb-el-metge-i-tractaments-personalitzats\/","og_site_name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","article_publisher":"https:\/\/www.facebook.com\/farmaceuticsbcn\/","article_published_time":"2013-09-12T09:19:27+00:00","author":"wpAdminCofbOrg","twitter_card":"summary_large_image","twitter_creator":"@farmaceuticsbcn","twitter_site":"@farmaceuticsbcn","twitter_misc":{"Escrito por":"wpAdminCofbOrg","Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/novaorg.cofb.net\/2013\/09\/12\/futur-de-la-formulacio-magistral-comunicacio-amb-el-metge-i-tractaments-personalitzats\/#article","isPartOf":{"@id":"https:\/\/novaorg.cofb.net\/2013\/09\/12\/futur-de-la-formulacio-magistral-comunicacio-amb-el-metge-i-tractaments-personalitzats\/"},"author":{"name":"wpAdminCofbOrg","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb"},"headline":"Futur de la formulaci\u00f3 magistral: comunicaci\u00f3 amb el metge i tractaments personalitzats","datePublished":"2013-09-12T09:19:27+00:00","dateModified":"2013-09-12T09:19:27+00:00","mainEntityOfPage":{"@id":"https:\/\/novaorg.cofb.net\/2013\/09\/12\/futur-de-la-formulacio-magistral-comunicacio-amb-el-metge-i-tractaments-personalitzats\/"},"wordCount":510,"commentCount":0,"publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"image":{"@id":"https:\/\/novaorg.cofb.net\/2013\/09\/12\/futur-de-la-formulacio-magistral-comunicacio-amb-el-metge-i-tractaments-personalitzats\/#primaryimage"},"thumbnailUrl":"","keywords":["Formulaci\u00f3 magistral"],"articleSection":["Not\u00edcies farm\u00e0cia"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/novaorg.cofb.net\/2013\/09\/12\/futur-de-la-formulacio-magistral-comunicacio-amb-el-metge-i-tractaments-personalitzats\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/novaorg.cofb.net\/2013\/09\/12\/futur-de-la-formulacio-magistral-comunicacio-amb-el-metge-i-tractaments-personalitzats\/","url":"https:\/\/novaorg.cofb.net\/2013\/09\/12\/futur-de-la-formulacio-magistral-comunicacio-amb-el-metge-i-tractaments-personalitzats\/","name":"Futur de la formulaci\u00f3 magistral: comunicaci\u00f3 amb el metge i tractaments personalitzats - Col\u00b7legi de Farmac\u00e8utics de Barcelona","isPartOf":{"@id":"https:\/\/www.cofb.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/novaorg.cofb.net\/2013\/09\/12\/futur-de-la-formulacio-magistral-comunicacio-amb-el-metge-i-tractaments-personalitzats\/#primaryimage"},"image":{"@id":"https:\/\/novaorg.cofb.net\/2013\/09\/12\/futur-de-la-formulacio-magistral-comunicacio-amb-el-metge-i-tractaments-personalitzats\/#primaryimage"},"thumbnailUrl":"","datePublished":"2013-09-12T09:19:27+00:00","dateModified":"2013-09-12T09:19:27+00:00","breadcrumb":{"@id":"https:\/\/novaorg.cofb.net\/2013\/09\/12\/futur-de-la-formulacio-magistral-comunicacio-amb-el-metge-i-tractaments-personalitzats\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/novaorg.cofb.net\/2013\/09\/12\/futur-de-la-formulacio-magistral-comunicacio-amb-el-metge-i-tractaments-personalitzats\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/novaorg.cofb.net\/2013\/09\/12\/futur-de-la-formulacio-magistral-comunicacio-amb-el-metge-i-tractaments-personalitzats\/#primaryimage","url":"","contentUrl":""},{"@type":"BreadcrumbList","@id":"https:\/\/novaorg.cofb.net\/2013\/09\/12\/futur-de-la-formulacio-magistral-comunicacio-amb-el-metge-i-tractaments-personalitzats\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inici","item":"https:\/\/novaorg.cofb.net\/"},{"@type":"ListItem","position":2,"name":"Futur de la formulaci\u00f3 magistral: comunicaci\u00f3 amb el metge i tractaments personalitzats"}]},{"@type":"WebSite","@id":"https:\/\/www.cofb.org\/#website","url":"https:\/\/www.cofb.org\/","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","description":"","publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cofb.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.cofb.org\/#organization","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","url":"https:\/\/www.cofb.org\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","contentUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","width":500,"height":105,"caption":"Col\u00b7legi de Farmac\u00e8utics de Barcelona"},"image":{"@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/farmaceuticsbcn\/","https:\/\/twitter.com\/farmaceuticsbcn","https:\/\/www.instagram.com\/farmaceuticsbcn\/","https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/"]},{"@type":"Person","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb","name":"wpAdminCofbOrg","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g","caption":"wpAdminCofbOrg"},"sameAs":["http:\/\/192.168.64.122\/wordpress"],"url":"https:\/\/www.cofb.org\/es\/author\/wpadmincofborg\/"}]}},"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false,"trp-custom-language-flag":false},"uagb_author_info":{"display_name":"wpAdminCofbOrg","author_link":"https:\/\/www.cofb.org\/es\/author\/wpadmincofborg\/"},"uagb_comment_info":0,"uagb_excerpt":"\u201cHi ha molts pacients que necessiten l\u2019adequaci\u00f3 dels tractaments i la formulaci\u00f3 magistral n\u2019\u00e9s una resposta: aquesta \u00e9s una de les raons per les quals t\u00e9 una excel\u00b7lent perspectiva en els propers anys\u201d. S\u00f3n paraules de Francesc Llamb\u00ed, president d\u2019Aprofarm i vocal del Col\u00b7legi de Farmac\u00e8utics de Barcelona, qui ha [&hellip;]","_links":{"self":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/posts\/68799","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/comments?post=68799"}],"version-history":[{"count":0,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/posts\/68799\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/"}],"wp:attachment":[{"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/media?parent=68799"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/categories?post=68799"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cofb.org\/es\/wp-json\/wp\/v2\/tags?post=68799"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}